Zusammenfassung (Niederländisch oder Französisch oder Englisch)
Trial Description
| Title | A pHase III cluster randomIsed controlled, cross-over, non-inferiority Trial of a short course, High dose AntimicRobials vs conventional dose and Duration in critically ill patients |
| Participants (P) | Patients in ICU, treated for Community acquired Pneumonia (CAP), Hospital acquired pneumonia (HAP), Ventilator Acquired Pneumonia (VAP) and Intra- abdominal Infection (IAI) (with adequate source control) or Bloodstream Infection (BSI) with one of the following antimicrobials: ceftriaxone, cefotaxime, cefuroxime, piperacillin-tazobactam or meropenem. |
| Intervention (I) | High dose short duration of the antibiotics |
| Control (C) | Standard antibiotic dose and duration |
| Outcome (O) | All cause 90-day mortality |
| Trial Design | A prospective non-inferiority, multicentre, cluster-randomized, cross-over study |
| Sample Size | 1282 patients |
| Trial duration | 42 months |
| Budget | 1,5 MIO EURO |
Trial team
| Sponsor | UZ Gent |
| Chief Investigator | Prof dr Jan De Waele |
| External partners | Dutch Coordinating Centre Radboud University Medical Centre |
| Number of participating sites | 7 |
DOCUMENTS
References
CTIS number: 2024-514730-21-00
Webpage: https://hithardstudy.eu/
Funding scheme
